Banner

Products

All Products SARS-CoV-2 Related Products Luciferase-GFP Spike (SARS-CoV-2) Pseudotyped Lentivirus

Luciferase-GFP Spike (SARS-CoV-2) Pseudotyped Lentivirus

Catalog# Unit Unit Price (USD) Actions
SV11 5 x 20 µl, concentrated $1950 Add to Cart
Highlights:
  • Safe - BSL2 conditions appliable
  • Multiple choices of 3rd-generation lentivector reporter(e.g., GFP, Luciferase) to meet your requirement
  • Ideal for COVID-19 research, such as virus infectivity study, drug screen (neutralization assays), vaccine
Applications:
  • Vaccine development for prevention of infection by SARS-CoV-2 virus
  • Studying the efficacy and mechanism of neutralizing antibodies against SARS-CoV-2 virus
  • Development of anti-coronavirus therapeutic agents
  • Studying the mechanism of virus-receptor interaction
Description:

The Spike (SARS-CoV-2) pseudotyped lentivirus was produced with SARS-CoV-2 Spike protein as the envelope glycoprotein instead of vesicular stomatitis G (VSV-G) envelope glycoprotein. These pseudoviruses also contain Luciferase gene driven by CMV promoter and GFPT2A-puro driven by EF1α promoter, therefore, the spike-mediated cell entry can be conveniently quantified by luciferase activity and visualized under a fluorescent microscope. The Spike (SARS-CoV-2) pseudotyped lentivirus can be used for studying basic mechanisms and drug development including measuring the activity of neutralizing antibody against SARS-CoV-2, and screening anti-CoV2 drugs in a Biosafety Level 2 facility

Background

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Infection of SARS-CoV-2 to human cells is initiated by the binding of its Spike protein to ACE2 (angiotensin converting enzyme 2), a homodimer receptor, on the surface of some human cells, particularly those in the respiratory tract. The Spike protein promotes attachment of ACE2 to the subunit S1 and its RBD (Receptor Binding Domain) region, facilitates fusion of the viral and cellular membrane releasing the virus core into the cell. Therefore, drugs targeting the interaction between the Spike protein of SARSCoV-2 and ACE2 may offer protection against the viral infection. Due to the highly transmissible and pathogenic nature of SARS-CoV-2, handling of live virus requires a biosafety level 3 (BSL3) containment. In order to extend this capability to BSL-2, a high titer pseudotype virus is needed to meet such requirement that effectively replaces the need for the live SARS-CoV-2.

Literature:
  1. Crawford, K.H.D., et al., Viruses, 2020. 12(5).

images/Desc_Images/SV11_1.png
Luciferase pseudotyped lentivirus assay. GFP expression was detected in HEK293-hACE2 cells as early as 24 hours after transduction by Luciferase Spike (SARS-CoV-2) pseudotyped lentivirus while no GFP expression was detected in HEK293 WT cells. Strong GFP expression can be observed in HEK293-hACE2 cells 48-72 hours post-transduction. This infectivity of ALSTEM pseudotyped lentivirus is significantly higher than what has been reported in the literature1.
images/Desc_Images/SV11_2.png
Luciferase assay. Transduction of HEK293-hACE2 cells and HEK293 wild type using Luciferase Spike (SARS-CoV-2) Pseudotyped Lentivirus.
Specifications:
Product Name Luciferase-GFP Spike (SARS-CoV-2) Pseudotyped Lentivirus
IFU

~5X106 IFU/ml

Shipping Condition

Dry Ice - Overnight

Storage and Stability

Store at -80°C

Restricted Use

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Antibody neutralization assay

images/Application_Images/SV11_1.png
Schematic Representation of the Neutralization Assay
images/Application_Images/SV11_2.png
Antibody neutralization assay. Luciferase Spike (SARS-CoV-2) Pseudotyped Lentivirus was incubated with anti-SARS-CoV-2 spike protein antibodies (ALSTEM, SAb-401.1, Cat# COV2S41) and subsequently inoculated onto HEK293-hACE2 cells (ALSTEM, Cat# AL01) to evaluate cross-neutralization potential. The antibody against SARS-CoV-2 spike protein is able to effectively inhibit the infection of pseudovirus to the target cells (IC50 = 16.2 ng/ml).